Sotatercept shows promise for a type of pulmonary hypertension linked to heart failure with preserved EF

Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary hypertension) experienced significant improvements in blood pressure and vascular health after taking the drug sotatercept, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26). The study was simultaneously published online in Circulation.